



PALTmed Colorado (CMDA) 31st Annual Conference April 24, 2026



More information available [here](#).

[Registration Page](#)



PPA Event Center
Friday, April 24, 2026

JOIN US IN-PERSON OR LIVESTREAM!



www.cmda.us



Pikes Peak Ethics Committee Meeting

- First Friday of every month at noon.
 - Please consider bringing a case to the meeting. It's a great opportunity to discuss difficult cases with your peers in LTC, share experiences, and learn from each other.
 - Email me if you would like to be added to our email list to receive the agenda and reminders about the meeting.
 - <https://zoom.us/j/97461641616?pwd=YPPjU1ZHMG3bTChSVxAcD9gb39qVaY.1>
-

Survey updates

- **Falls are a focus.**
 - Colorado State average for falls is higher than the national average. Surveyors are focusing on falls.
- **Holding Medications**
 - Please ensure appropriate documentation if we are holding a medication or if it is not available for any reason, such as a pending prior authorization.
 - If there is an order to give a medication, we must call the physician to get an order to hold the medication if it is not available for any reason. Alternatively, ask the physician if there is an alternate therapeutic option.

[QAPI guide](#)

COVID / Influenza / RSV update

- RSV activity still rising and we are still seeing influenza activity, but I think it is declining.



Viral Respiratory Diseases Data

Colorado monitors statewide influenza, COVID-19, and respiratory syncytial virus activity throughout the year. For influenza and RSV, Colorado conducts additional enhanced monitoring each viral respiratory season between October and May. Currently, all statewide COVID-19 surveillance activities are conducted year-round.

This Week's Overview


Overall respiratory illness activity in Colorado is **Moderate**

For more information, visit [CDC's Respiratory Illness Data Channel](#)

Hospital Admission Rates

Syndromic Data

Colorado COVID-19, Influenza, and RSV Hospital Admission Rates by Week of Admission



Key Metric Changes This Week Compared to Last Week

Pathogen	ED Visits Diagnosed	Weekly Sentinel Positivity Rate
COVID-19	0.38% (▼0.17)	3.23% (▼0.7)
Influenza*	2.00% (▼0.04)	13.00% (▲0.99)
RSV	0.73% (▼0.1)	13.06% (▲0.13)

*B is the predominant circulating virus.

Wastewater Surveillance Data

SARS-CoV-2	Influenza	RSV
Increasing SARS-CoV-2 trends in 2 out of 21 monitored utilities.	Influenza detected in 13 out of 21 monitored utilities.	Respiratory Syncytial Virus (RSV) detected in 16 out of 21 monitored utilities.

Pneumonia Vaccination Recommendation

- **PCV21 should be the first choice.** PCV20 is an alternative.
- I would recommend PCV21 over PCV20. However, if a patient has already gotten PCV20, I would not “re-vaccinate” with PCV21 unless the patient wanted to do so. If you already have PCV20 or if it is cheaper, I think it is a justifiable alternative. PCV21 should be the first choice.

I continue to recommend PCV 21 for pneumonia vaccinations. There are some pharmacies that may have read the “fine print” on the PCV 21 information sheet and will tell you that Colorado is one of the states where PCV 21 may not be as good as the PCV 20 vaccine. I think that information is on the package insert and is a footnote in some vaccination tables. Here’s why. PCV21 does not cover serotype 4 Streptococcal Pneumoniae but PCV 20 does. However, I reviewed the actual data on serotype 4 prevalence at one point



and surmised that there is not that much serotype 4 in Colorado and especially not in our population. Unfortunately, I did not download that data and cannot find it on the CDC website now. So, I conferred with an epidemiologist at CDPHE. They have confirmed that **Colorado has not seen enough serotype 4 disease to preferentially recommend PCV 20. In fact, in our LTC population with multiple comorbidities, PCV 21 is probably a better choice. They continue to monitor this issue.**

QUALITY INNOVATION NETWORK-QUALITY IMPROVEMENT ORGANIZATION (QIN-QIO)

- Telligen is leading this program.
- There are LTC facilities that CMS has targeted for inclusion in this program.
- There also may be opportunities to take part in the program if you have not been targeted.
- Details -> [Telligen Midwest QIN-QIO – docShepherd](#)

[Telligen Midwest QIN-QIO](#)

CONNECT WITH THE MIDWEST QIN-QIO

To connect with a member or our team or to inquire about partnership, events or available resources, please scan the QR Code and complete the form.



Telligen in partnership with Mountain Pacific are responsible for quality improvement work in each of the 14 states in the Midwest Region. This includes planning and implementing hands-on technical assistance to CMS-identified healthcare facilities that include hospitals, nursing homes, and outpatient clinical practices to meet the clinical aims and priorities established by CMS.



FOCUS AREAS

Midwest QIN-QIO assists nursing homes with the following **foundational & clinical priorities at no cost.**



Health IT

Enhance data exchange and utilization to strengthen communication across care settings, improve outcomes and empower residents to access and use health information.



Disease Prevention

Providing evidence-based immunization strategies and best practices that are critical to implementing a successful vaccination program



Patient Safety

Improving resident care, medication safety, and infection prevention and control



Behavioral Health

Sharing emerging evidence-based practices and resources for depression and substance use disorders



Emergency Preparedness

Identifying hazards, assessing risks, and creating action plans to protect residents and staff



Care Coordination

Improving communication and discharge planning to reduce ED utilization and readmissions



Workforce Challenges

Addressing challenges in the workplace related to staffing, training, and retention

STRATEGIC GOALS WHEN PARTNERING WITH THE MIDWEST QIN-QIO



Participate in a selection of interventions & measures as part of a Quality Action Plan



Provide input into the best role for the QIN-QIO within their institution/practice



Receive subject matter expertise to achieve quality goals



Review data to identify opportunities to improve performance



Share any feedback and success stories about their experience

Things We Do for No Reason: Prescribing gabapentinoids for pain

[Journal of Hospital Medicine: Things We Do for No Reason- Full Article](#)



Gabapentinoids for Pain: Reevaluating a Common Habit

The Efficacy & Safety Gap

83% of prescriptions are off-label.

Most use is for pain conditions without FDA approval or proven clinical benefit.



Minimal clinical benefit for off-label pain. Most trials show less than a 1-point improvement on a 10-point pain scale.

Efficacy
(Clinical Benefit)



Safety Risks

7x higher risk of opioid overdose.

Combining gabapentinoids with opioids drastically increases fatal respiratory depression risks.

Clinical Action Plan



Implement a gradual tapering plan.

Deprescribe over 1–8 weeks to minimize withdrawal symptoms and reassess patient needs.



Use "N-of-1" trials for acute pain.

Only continue therapy if there is a clear, monitored, and significant reduction in pain.



Prioritize non-pharmacologic strategies.

Use physical therapy, exercise, and mindfulness as safer, effective alternatives for chronic pain.

© NotebookLM

What are gabapentinoids?

- Gabapentin and pregabalin — among the most prescribed drugs in the US (70M and 6.5M prescriptions in 2021, respectively)
- FDA-approved only for select conditions (postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, seizures)
- ~83% of prescriptions are off-label

The evidence against routine use:

- RCTs consistently show minimal or no benefit over placebo for most off-label pain conditions (back pain, sciatica, pelvic pain, postoperative pain, etc.)
- When benefits were found, they were often clinically insignificant (<1 point on a 0–10 pain scale)
- Pfizer paid billions in legal settlements for illegally promoting off-label use and suppressing negative trial data

Key harms and risks:

- Dizziness and sedation in up to one-third of users



- 7x increased risk of opioid overdose when combined with opioids
- Falls, delirium, respiratory depression, fractures
- Higher hospitalization risk, even at low doses
- Misuse and dependence, even at therapeutic doses
- Dangerous in renal impairment (renally cleared), yet dosing is often not adjusted

When they might still be considered:

- Postherpetic neuralgia and diabetic peripheral neuropathy (FDA-approved indications)
- Individualized “N-of-1” trials with clear goals, monitoring, and a plan to stop if ineffective

Recommendations:

- Don’t routinely prescribe gabapentinoids for pain
- Reassess at discharge and deprescribe when appropriate (taper over 1–2 weeks, or 4–8 weeks for long-term users)
- Prefer non-pharmacologic alternatives: physical therapy, cognitive-behavioral therapy, mindfulness, exercise

[Gabapentin for Pain:](#)